Skip to main content

BioPlus Acquisition Corp.

BIOSDelisted Oct 6, 2023
Industry
Electromedical & Electrotherapeutic Apparatus
SEC CIK
0001856653

BioPlus Acquisition Corp. was delisted on Oct 6, 2023; its insiders filed their last Form 4 on Jun 12, 2023; 30 institutions reported holding it in 13F filings for Q3 2023, worth $135.2M in total; no superinvestor held it.

Q3 2022 vs. Q2 2022

How the institutions holding BioPlus Acquisition Corp. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of BIOS: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders6567+2
Shares19.3M20.1M+802.3K (+4.2%)
Value$192.8M$201.7M+$8.95M (+4.6%)

New holders (8)

Institutions that held BioPlus Acquisition Corp. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to BIOS in Q3 2022
InstitutionSharesValue% of portfolio
Atalaya Capital Management LP250,000$2.51M0.34%
Aristeia Capital LLC232,256$2.33M0.04%
Parallax Volatility Advisers, L.P.221,829$2.23M0.04%
Spartan Fund Management Inc.149,285$1.50M0.46%
Wolverine Asset Management LLC40,270$404.0K0.01%
Karpus Management, Inc.34,135$342.0K0.01%
Clear Street LLC1,116$11.0K0.00%
Elequin Capital LP506$5.00K0.00%

Sold out (6)

Institutions that held BioPlus Acquisition Corp. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of BIOS in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Mangrove Partners405,141$4.03M
Weiss Asset Management LP205,000$2.06M
Basso Capital Management, L.P.145,001$1.44M
Union Square Park Capital Management, LLC50,000$499.0K
Eisler Capital (UK) Ltd.49,895$496.0K
Schonfeld Strategic Advisors LLC10,000$100.0K